Thromboxane (TX) A 2 is a prostaglandin produced by metabolism of arachidonic acid through cyclooxygenases and thromboxane synthase. TXA 2 is biologically active, mainly through activating its cognate, seven transmembrane, G protein coupled receptor. It was previously reported that thromboxane A 2 receptor (TP) was expressed in prostate cancer, and further activation of this receptor elicited cell contraction and modulated tumor cell motility through regulating small GTPase RhoA [1] . This study aims to identify G alpha protein(s) involved in thromboxane A 2 signaling in tumor cell motility.
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INTRODUCTION
Over the years prostate cancer has become the most common male malignancy and one of the leading cause of cancer death in American men [2] . Prostate cancer has been synonymous with low grade of replication potential along with old age. Median age for prostate cancer to develop is around 67 years (SEER Cancer Statistics). Overall there has been a decline in the rate of incidence of prostate cancer, it's not due to the fact that we have been able to find a cure for the cancer itself but due to better diagnostic tools or screening procedures [3] . Prostate cancer can be diagnosed with blood serum analysis for PSA, digital rectal exam and transurethral ultra-sonography (TRUS). Prostate cancer substantiates itself with an alteration of Prostate Specific Antigen (PSA) level in the blood and urinary dysfunction, along with impact on sexual function and performance.
The current modalities for treatments include surgery, radiation, and adjuvant hormonal therapy. Although these therapies are relatively effective, majority of patients diagnosed with localized prostate cancer ultimately recidivate. Therefore, the potential risk confronted by prostate cancer patients is the development of metastasis, which presents with additional symptoms, such as bone pain, weakness in legs, and urinary and fecal incontinence [3] . Immense efforts are underway to develop therapeutics for the treatment of prostate cancer metastasis. Epidemiologic studies have shown that individuals who take nonsteroidal anti-inflammatory drugs on a regular basis have a 40-50% reduction in mortality from colorectal cancer [4] . One trait common in all of the non steroidal antiinflammatory drugs is their ability to inhibit cyclooxygenase (COX), an enzyme required in the conversion of arachidonic acid to prostaglandins [5] . COX possesses two isoforms, COX-1 and COX-2 [6] . COX-1 and 2 is expressed at high levels in both bladder and prostate tumors in humans [7] , indicating a potential roles for COX in cancer progression.
Invasiveness of the prostate cancer was reduced by treatment with sulindac sulfone, a known COX inhibitor [8] . COX-1 is a constitutively expressed enzyme that generates prostaglandins (PG) and thromboxanes from arachidonic acid [5] . Thromboxane synthase which originates from arachidonic acid is being known as potent mediator of cancer cells metastasis [9] . TXA 2 stimulates platelet aggregation which is arbitrated by the activation of glycoprotein complex IIb/IIIa [10] .TXA 2 is readily hydrolyzed to the biologically inactive form TXB 2 in aqueous solution [11] . Due to its unstable nature, TXA 2 primarily functions in an autocrine or paracrine manner within vincity of production [12] . It has been shown that low dose of acetylsalicylic acid (asprin) which impedes the formation of TXA 2 by irreversibly inhibiting cyclooxygenase-1 (COX-1), exhibits 30% reduction in colorectal cancer [13] and possibly other cancers and esophageal cancer [4, 14, 15] including prostate cancer [13] .
TXA 2 is biologically active, mainly through its cognate, seven transmembrane, G protein coupled receptor [16] . Ligand binding to the G-protein-coupled receptors (GPCRs) transmit signals through conformational changes causing interaction with heterotrimeric GTP-binding proteins (G proteins), which in turn activates the downstream signaling cascades. After the activation of the receptor these signals are being further carried forward by the heterotrimeric G proteins, which are adhered to the inside surface of the cell membrane. Heterotrimeric G proteins consist of α, β and γ subunits. Upon activation of the G protein coupled receptor it induces a conformational change which manifest itself by acting as a guanine nucleotide exchange factor that exchanges GDP for GTP on the G alpha subunit, this action initiates the dissociation of G alpha from Gβγ dimer and its receptor [17] . It is known that thromboxane A 2 receptor (TP) which binds to its seven transmembrane G protein coupled receptor is expressed in prostate cancer, and further activation of this receptor elicit cell contraction and modulated tumor cell motility through regulating small GTPase RhoA [1] .
Based on these findings we hypothesized that G alpha subunits functions as upstream regulators of GTPase form of Rho A activity by responding to extracellular stimuli which manifest as modulating prostate cancer cell motility and cytoskeleton reorganization. G alpha subunit is divisible into four families: G alphas, G alpha i/o, G alpha q/11and G alpha12/13. G alpha12 and Galpha13, are the ones which are activated by various stimuli, such as thromboxane A 2 , lysophosphatidic acid (LPA), and thyroid-stimulating hormone receptors [18] [19] [20] [21] [22] . G alpha 12 and G alpha 13 are known to modulate variety of cellular processes, such as actin cytoskeleton reorganization, neurite retraction, platelet aggregation, and apoptosis [19, 21, 23, 24] . In spite of the fact that G alpha12 and G alpha 13 perform functions that coincide with each other however they seem to distinguish in their abilities to conjoin to different ligands for different physiological effectors [18, 21, 25]. Microarray analysis shows that G alpha12 is highly expressed in nasopharyngeal carcinoma [26] and it modulates the actin cytoskeleton reorganization which promotes highly invasive nature of these cancer [26, 27] .G alpha 12 stimulates multiple signaling pathways by the activation of the small GTPase Rho via specific Rho guanine nucleotide exchange factors (RhoGEFs) [27] . G alpha 12 stimulate Rho activity through LARG and PDZ-RhoGEF [27] .p115RhoGEF was the first RhoGEF to be recognized as a connection between G alpha 12/G alpha13 and Rho activation [28] . In small cell lung carcinoma, G alpha 12 and 13 have been known to promote invasiveness [29] . The ectopic expression of wild-type or an activated mutant of G alpha 12 causes cancerous transformation of fibroblast cell lines such as NIH-3T3 cells [30] . Multitude of studies shows that G alpha12 and G α13 plays an important role in terms of defining the downstream signaling cascade but there role with relation to thromboxane A 2 receptor activation was still ambiguous in prostate cancer cells. Since it has been proposed that gene modulation is one of the most sought after strategy since genomic instability leads to progression of cancer which later could result in its metastasis, so knockout experiments were being carried out which revealed that G alpha 13 depleted cells resulted in impaired angiogenesis and intrauterine death [31] . Knockdown of G alpha 12 has been reported to strongly activate the basal ERK, sustained activation of ERK results in DNA damage induced apoptosis [32] . These studies reflect that G alpha 12 and G alpha 13 might play a pertinent role in cellular signaling pathway in prostate cancer cells. Various methods can be employed to inhibit a gene expression, so far small hairpin RNA (shRNA) represents a considerable promise for cancer therapy due to its potent and specific knockdown effect [33] . In the present study, we intend to silence the G alpha 12 expression in prostate cancer cells using synthetic shRNA and evaluate its effects on tumor cell invasiveness and growth by employing both in vivo and in vitro experiments. 
MATERIALS AND METHODS

Materials
Cell Culture
Human prostate cancer cell lines (PC-3MM) were obtained from Dr Kounosuke Watabe.
PC-3MM cells were cultured in RPMI 1640 with 10% FBS and streptomycin (100 μg/mL). Cells were cultured in a humidified atmosphere containing 5% CO 2 at 37°C. The culture medium was replaced every 2-3 days, and the cells were treated with PBS in order to lift them up when they reached 80~90% confluence.
Transfection of wild type and constitutively active G alpha subunits
PC-3MM Cells were transfected with wild type and constitutively active form of G alpha subunits (G alpha i1, q, 12, 13 and 11) using QS transfection reagent. Cells were seeded in a 6-well plates at a density of 0.5×105 cells/ well in RPMI 1640 medium containing 10% FBS and streptomycin (100 μg/mL). 1µg of G alpha subunit was mixed with 2 μl QS transfection reagent along with 100 μl of FBS free medium RPMI1640, it was incubated at room temperature for 15 min to form a complex. The cell culture medium was then removed, and 103µl of Gα/QS transfection complex was added drop wise to the cells. After twenty-four hours, transfection medium was replaced with fresh RPMI-1640 medium containing 10% FBS, and streptomycin.
G alpha 12 shRNA Constructs
Two predesigned commercially available shRNAs (shRNA 909 and shRNA911) were purchased from Origene, Inc (Rockville, MD). These shRNAs are of 29 nucleotides each one having a sequence as shRNA909 (TGGTGGAGTCCATGAACATCTTCGAGACC) and shRNA911 (CTGCTGGAGTTCCGCGACACCATCTTCGA). Both of these predesigned shRNA sequences were verified against the human genome database to annihilate cross linking with other-target genes. Scrambled shRNA was purchased from
Origene, Inc and it was used as a negative control.
Transfection of G alpha12 shRNA
PC-3MM Cells were transfected with shRNA using QS transfection reagent. Cells were seeded in a 6-well plates at a density of 0.5×105 cells/ well in RPMI 1640 medium containing 10% FBS and penicillin/streptomycin (100 μg/mL). After 24 hours, cells were transfected with shRNA using QS transfection reagent. 1µg of shRNA was mixed with 2 μl QS transfection reagent along with 100 μl of FBS free medium RPMI 1640; it was incubated at room temperature for 15 min to form a complex. The cell culture medium was then removed, and 103µl of shRNA/QS transfection complex was added drop wise to the cells. After twenty-four hours, transfection medium was replaced with fresh RPMI-1640 medium containing 10% FBS, and streptomycin.
Real-Time RT-PCR
Total RNA was isolated from cell pellets using TRIzol reagent (Invitrogen) as per the manufacturer's protocol. RNA (1µg) was converted to cDNA using dNTP, primers, and Taq To confirm the knockdown of G alpha 12 we performed quantitative PCR, 1 microgram of cDNA was amplified using SYBR Green Master mix on 7500 Real Time PCR System by Applied Biosciences (Foster City, CA). PCR products were subjected to a meltingcurve analysis. Comparative threshold (Ct) method was used to calculate the relative amount of mRNA of treated sample in comparison to control samples. Each sample was performed in triplicate, and the mean value was calculated.
Cell Contraction Assay
PC-3MM cells (10,000 cells/well) were plated at low density in 6 well plate and incubated at 37 o C in a humidified environment having 5% of CO 2. Cells were placed under serum free condition for 24 hours. Replace the media and put 300nMol U46619 
Western Blot Analysis
PC-3MM cells transfected with the G alpha 12 shRNA for 24 h, 48 h post transfection, protein was isolated using 2x SDS buffer which contains protease and phosphtase inhibitor. Same amount of total protein was used for all the samples and was separated on a SDS PAGE gel (percentage of gel depended on the molecular weight of the protein).
The separated proteins were transferred to a nitrocellulose membrane, blocked, and probed with appropriate antibodies. The protein bands were then visualized using secondary antibodies. The membranes were later scanned with Odyssey infrared analyzer.
Wound-Healing Assay
PC-3MM cells were seeded in 6-well plates, Once the cells reached 90% confluency, using a (yellow) pipette tip make a straight scratch which simulates a wound by keeping the tip under an angle of around 30 degrees to keep the scratch width limited. The detached cells were removed by washing with PBS. Then, the cells were incubated in the incubator supplemented with 5% CO 2 at 37°C. The wound-healing process was monitored microscopically over the period of time as the cells moved into the wound area, and the images were taken from the same place at various intervals using an inverted microscope.
Cell Migration Assay
The effect of shRNA on invasiveness and metastatic potential of prostate cancer cells was evaluated using Boyden Chamber assay .Twenty-four hours after seeding the PC-3MM cells. They were treated with PBS in order to lift them up and later it was re-suspended in each group had three samples.
Tumor cell lines & in vivo experiments
The PC-3MM cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and penicillin/streptomycin(100µg/ml). 
Statistical Analysis
Student's t test was employed to examine the difference between two groups. Data was expressed as the mean ±standard deviation (SD). P<0.05 was considered statistically significant.
RESULTS
Endogenous expression of G alpha subunits in PC-3MM
The endogenous expression of G alpha subunits was analyzed by real time PCR.G alpha subunits were amplified from the cDNA which was synthesized from mRNA by reverse 
G alpha12 and G alpha 13 activation causes actin cytoskeletal reorganization
In order to determine the role of G alpha subunits in thromboxane A 2 signaling, we expressed different alleles of G alpha proteins (wild type, constitutive active) in PC3MM cells and then the subsequent effects on cell contraction were determined. The rationale behind transfecting the constitutively active form was to use it as a reference control since it would exhibit its effect even in the absence of the ligand. It was observed that overexpression of G alpha 12/13 increased cell contraction after activation of thromboxane A 2 receptor, when treated with U46619. Expression of constitutively active G alpha 12 (Fig 2A) or G alpha 13 ( Fig 2B) was sufficient to cause cell contraction, regardless whether TP is activated or not. Cells that exhibited rounded morphology having the length twice less than its width were counted.
Inhibition of U46619 induced cell contraction by G alpha Q
Profiling of G alpha subunits revealed a loss of G alpha Q in PC-3 or PC-3MM cells.
U46619 induces cell contraction in PC-3 or PC-3MM cells efficiently but not in DU145
cells, even though DU145 cells express receptors for thromboxane A2. We hypothesize that G alpha Q may attenuate TP signaling to cell contraction. To test this hypothesis, PC-3MM cells were transfected with expression constructs for G alpha Q or constitutively active G alpha Q and then treated with U46619. Cells were then fixed, stained, and scored for contraction. As shown in Figure 3 , restoration of G alpha Q or expression of active G alpha Q blocked U46619 induced cell contraction. Untransfected cells were used as controls. The results suggest that G alpha Q subunit inhibits U46619-induced cell contraction.
Suppression of G alpha 12 with commercially available shRNAs
Two commercially prepared synthetic shRNAs that would target human G alpha 12 
Suppression of G alpha 12 Inhibits Cell Motility
We investigated the effect of G alpha 12 inhibition on cell motility and invasiveness of prostate cancer cells. Wound-healing assay is an in vitro assay which portrays the in vivo shRNA still had an unhealed gap (Fig 6) , indicating that depletion of G alpha 12 can efficiently suppress the motility of prostate cancer cells.
Depletion of G alpha 12 inhibits cell migration
We investigated the effects of G alpha 12 depletion on the migrating abilities of prostate cancer cells. Migration of metastatic tumor cells towards a chemo-attractant is trademark of these cells, and it is considered to be an essential step for tumor invasion and metastasis. The migration ability of PC-3MM cells was analyzed using Boyden chamber assay, which is a model to imitate the in vivo metastatic process. As shown in Fig.7 
Effect of G alpha 12 depletion on Cell cycle
We performed cell cycle analysis to determine whether knockdown of G alpha 12 precede to changes in the cell cycle distribution of prostate cancer cells. Cells transfected with G alpha 12 shRNAs in comparison to scrambled shRNA treated cells effectuate a block in G1/G0 phase distribution. The percentages of cells in G1/G0 phase in cells having depleted G alpha 12 for both the clones (shRNA 909,shRNA 911) were 53% and 64% , whereas 44% having scrambled shRNA were in G1/G0 phase. This G1/G0 phase was accompanied by repression in G2/M and S phase distribution in both G alpha 12 depleted cells. This difference in G1/G0 phase is statistically significant (p=0.05). The results of cell cycle analysis are consistent with findings of the cell proliferation assay.
These results demonstrated that G alpha 12 inhibition negatively regulates cell proliferation in prostate cancer as shown in Fig 9 .
Effect of G alpha 12 inhibition on EMT associated genes
Whenever a metastasis takes place in primary cancer it is always preceded by a complimentary change which is called as epithelial to mesenchymal transition (EMT).
EMT causes transient morphologic and biological changes in cells that will alter cell motility and contact with neighboring cells [34] . The knockdown of G alpha 12 in PC-3
MM causes increased expression of all those markers which causes increased cell-cell interaction such as E cadherin and claudin 1 along with concomitant decrease in the expression of the vimentin, snail, snail 2, beta catenin, MMP9, MMP2(matrix metalloprotease), Zeb 1(Zinc finger E box binding homeobox binding 1), fn 1(fibronectin), fsp 1(fibroblast secretory protein) and sip 1 (Fig 10) . These results were further verified by western blot. Taken together these results reflect that inhibition of G alpha 12 reduces EMT.
Effects of G alpha 12 suppression on tumor growth and progression
In order to confirm our in vitro findings we carried out in vivo experiments in nude mice. 
DISCUSSION
It is known that in order to metastasize, cancer cells need to acquire motility. During cell migration, a cell contracts at the trailing edges. Cytoskeleton reorganization is also required for the the formation of lamellipodia and fillopodia (cytoskeleton actin protein) [35] . Rho A is a small GTPase regulated protein known to control the actin cytoskeleton structure which results in the formation of stress fibers. Rho A modulates the actin cytoskeleton reorganization by activating ROCK which ends up activating cofilin through LIM kinase activation [36] .
It has been shown that TXA 2 by binding to its cognate G protein coupled receptor causes the activation of RhoA which goes on to bring about actin cytoskeleton reorganization and manifests in the form of cell motility [1] . Since G protein coupled receptors channelize there activation through the heterotrimeric G proteins so we proposed that G alpha subunits might be the one regulating the downstream signaling of Rho A.
Principally there are four different G alpha subunits which can regulate the downstream signaling cascade such as G alpha s, G alpha i/o, G alpha q/11and G alpha12/13. We were not sure as to which subunit is regulating the activation of RhoA when TXA 2 ligand binds to its receptor.
In this study we explored that activation of the G alpha subunit is a critical step in the activation of Rho A and G alpha 12 is an important upstream regulator of the Rho A activation. G alpha 12 has been identified to play a major role in the metastasis of breast and nasopharyngeal cancers [26] , though there role was still undeterminate in prostate cancer in relation to activation through TXA 2 .
In this study, we demonstrated that G alpha 12 shRNA even in the presence of U46619
(structural analog of TXA 2 ) significantly decreases invasiveness of prostate cancer cells.
We examined the effect of G alpha 12 depletion by two predesigned shRNAs in prostate cancer cells which was verified using real time RT-PCR and western blot analysis. Two commercially prepared potent shRNAs, shRNA-909 and shRNA-911 were utilized to investigate their biological effects on prostate cancer cells. It is generally believed that G alpha 12/13 promotes the invasiveness as well as cell proliferation human small cell lung carcinoma in vitro and tumor growth in vivo [29] . We then analyzed the effect of G alpha Kumar and colleagues reported the role of G alpha 12 in soft tissue sarcomas as to be a putative causative oncogene and over expression of wild type or GTPase deficient mutant of G alpha 12 causes oncogenic transformation of NIH3T3 cells [37] . This oncogenic transformation in NIH3T3 cells manifests by increased rate of cell proliferation, anchorage independent growth, decreased growth factor dependency and cytoskeletal changes [34] . They showed that suppression of PDGFR alpha and JAK3
rarefied the mutant G alpha 12 activity [34] . So they proposed that PDGFR alpha and JAK3 provide an autocrine/paracrine loop for activation in G alpha 12 mediated cell proliferation. Based on these findings we performed three assays(MTS assay, BrdU
Incorporation assay and Trypan blue cell proliferation assay) to depict the effect of G alpha 12 inhibition on the rate of cell proliferation in PC-3MM cells. As expected scramble control cells showed greater rate of cell proliferation as compared to the cells having a stable knockdown of G alpha 12. This result is in conformity with a report that knockdown of PDGFR alpha and JAK3 attenuated G alpha 12 and affected the rate of cell proliferation [3] . To further confirm these results, we performed cell cycle analysis.
We observed that cells having a stable knockdown of G alpha 12 in comparison to scramble control showed slightly high distribution in G1/G0 phase, with a concomitant decrease in the cell population in S and G2/M phase. The difference is statistically significant from the control group. These results suggest that G alpha 12 shRNA has a significant effect on cell proliferation of PC-3MM cells.
Recently it has been reported that invasive phenotype is necessary for cells to cause bone metastasis [38] . Epithelial to mesenchymal transformation(EMT) in prostate cancer cells plays a pertinent role in not only prostate cancer maintenance but also bone metastasis and it is functionally associated with prostate cancer stem cells [38] . So we performed a quantitative analysis for the EMT associated genes, results show that G alpha 12 depleted cells in comparison to scramble control cells showed higher expression of those genes which modulates the cell-cell interaction (e cadherin and claudin) as a consequence it increased the E cadherin/vimentin ratio hence trying to restrict cells from acquiring mesenchymal trait which modulates the metastatic potential of prostate cancer cell line.
We performed in vivo experiments in order to validate our in vitro findings. In vivo studies carried out suggest that silencing of G alpha 12 and 13 leads to reduced tumor growth in comparison to control cells in Small cell lung carcinoma (SCLC) [29] . Results acquired after 4 weeks reflect that mice injected with knockdown clones of G alpha 12
showed slower growth rate in comparison to control cells.
In summary, results from this study provided significant evidence that G alpha 12 plays a pivotal role in the metastasis of prostate cancer cells. Considering the fact that the major risk faced by prostate cancer patients is the development of metastasis [39] , the G alpha 12 shRNA may provide a very promising approach for prostate cancer therapy. Fig6. Effect of suppression of G alpha 12 on cell motility. Wound healing assay was performed in order to ascertain the effect on cell motility in PC-3 MM cells after silencing G alpha 12.PC-3 MM cells were seeded in a 6 well plate. Cell monolayer was disturbed by producing a scratch when cells reached 90% confluency. After 8 hours, scramble control cells which were treated with U46619 showed increased ability to close the gap in comparison to the cells which had a stable knock down of G alpha 12.Closing of the gap was closely monitored at different time points using an inverted microscope at 200x. 
